sGC Stimulator Synthesis with pH-Controlled High-Purity Intermediates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for efficient processes that can produce stable and high-purity sGC stimulators suitable for large-scale manufacturing, as current therapies targeting the NO pathway have limitations and there is a demand for NO-independent sGC activators.
Innovation Solution
Novel processes for preparing compounds of Formula I, including coupling amides with pyrimidine compounds in aprotic solvents with bases, followed by quenching and pH adjustments, to form intermediates and final sGC stimulators, which can be scaled up for large-scale production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional synthesis processes are used for sGC stimulators, then the manufacturing complexity is reduced, but the product purity and stability are insufficient
Solution Approach 1:
The synthesis process is divided into multiple discrete steps with specific pH control zones (pH > 5 for cyclization, then acidification to pH 2-4 for isolation). Each step produces a distinct intermediate that can be separately optimized and controlled, enabling high purity through staged purification rather than attempting single-step synthesis.
Solution Approach 2:
The patent employs systematic parameter changes throughout the synthesis: starting with pH > 5 to enable cyclization, then adjusting to pH 2-4 for isolation, and controlling temperature and solvent conditions at each step. These parameter transitions enable selective formation of desired products while minimizing byproducts, achieving high purity without excessive process complexity.
2Productivity
If current synthesis methods are applied, then the process simplicity is maintained, but the scalability for large-scale manufacturing is limited
Solution Approach 1:
The patent performs preliminary actions by establishing optimal pH conditions (> 5) and solvent systems before initiating the cyclization reaction. Intermediate products are prepared and characterized in advance, allowing the process to be scaled systematically. The pre-established protocol enables straightforward translation from laboratory to manufacturing scale without requiring complex process re-optimization.
3Stability of the object's composition
If existing sGC stimulator production processes are used, then the manufacturing cost is reduced, but the product stability and purity are compromised
Solution Approach 1:
The synthesis protocol maintains continuous useful action by keeping the reaction mixture at pH > 5 throughout the cyclization phase, preventing premature precipitation or decomposition. The acidification step is performed continuously while monitoring purity, ensuring stable product formation. This continuous control approach maintains product stability without requiring complex intermittent processing steps.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These processes yield stable and high-purity sGC stimulators, enabling effective treatment of diseases through NO-independent mechanisms, suitable for large-scale manufacturing.
Implementation Method 1
coupling an amide of formula (1) with a pyrimidine compound of formula (2) in an aprotic organic solvent in the presence of a base, to form, after quenching with an acid, an intermediate of formula (3)
Implementation Method 2
at a pH >5, optionally in the presence of added N,O-dimethylhydroxylamine or a salt (e.g., hydrochloride salt) thereof, allowing the mixture to react to form the compound of formula (4)
Data Source
AI summary
The present disclosure relates to novel processes for the preparation of compounds of Formula I. Some of these compounds are useful as stimulators of soluble guanylate cyclase (sGC). Others are useful intermediates towards the preparation of said stimulators. These processes are amenable to large scale preparation and produce stable 3-(2-pyrimidinyl)pyrazoles of Formula I in high purity and yields. The present invention has the additional advantage of facile reaction conditions, amenable to scale up for large scale manufacturing. The disclosure also provides novel intermediates useful in the preparation of said compounds.